Bortezomib-Induced Myopathy in Multiple Myeloma: A Case Report
Sangwoo Kim, So Jin Kwak, Minseong Park, Ji Hye Hwang, Yu Jin Im
Samsung Medical Center Sungkyunkwan University
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Bortezomib is a widely used proteasome inhibitor for multiple myeloma, and its neurotoxicity, particularly peripheral neuropathy, is well recognized. By contrast, bortezomib-induced myopathy has rarely been reported and remains underrecognized in clinical practice. We describe a biopsy-supported case of bortezomib-induced myopathy in a patient with multiple myeloma who presented with progressive proximal lower-extremity weakness. A 68-year-old woman with multiple myeloma developed progressive bilateral proximal lower-extremity weakness approximately 6 weeks after starting bortezomib-based chemotherapy. Neurologic examination showed predominant proximal weakness, preserved distal strength, and no sensory deficits. Needle electromyography demonstrated myopathic motor unit potentials with early recruitment and no abnormal spontaneous activity. Serum creatine kinase levels were within the normal range. Biopsy of the left vastus medialis showed myofiber size variability, degenerating myofibers with lipid-laden microvacuoles, and moderate atrophy involving both type 1 and type 2 fibers, without selective type 2 fiber atrophy; these findings were consistent with bortezomib-induced myopathy. After bortezomib was discontinued, the patient showed gradual clinical and electrophysiologic improvement. This biopsy-supported case underscores the need to consider bortezomib-induced myopathy in patients with multiple myeloma who develop unexplained proximal muscle weakness. Early recognition is important because withdrawal of the offending agent may allow functional recovery.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Multiple Myeloma Research and Treatments
Muscle Physiology and Disorders · Cancer Treatment and Pharmacology